The affinity and selectivity of α‐adrenoceptor antagonists, antidepressants, and antipsychotics for the human α1A, α1B, and α1D‐adrenoceptorsRichard G. W. Proudman, Jillian G. Baker, André Sampaio Pupo|Pharmacology Research & Perspectives|2020Cited by 51
The signaling and selectivity of α‐adrenoceptor agonists for the human <scp>α2A</scp>, <scp>α2B</scp> and <scp>α2C</scp>‐adrenoceptors and comparison with human α1 and β‐adrenoceptorsRichard G. W. Proudman, Jillian G. Baker, Juliana Akinaga|Pharmacology Research & Perspectives|2022Cited by 26
The pharmacological effects of the thermostabilising (m23) mutations and intra and extracellular (β36) deletions essential for crystallisation of the turkey β-adrenoceptorJillian G. Baker, Christopher G. Tate, Richard G. W. Proudman|Naunyn-Schmiedeberg s Archives of Pharmacology|2011Cited by 26
Salmeterol’s Extreme β2 Selectivity Is Due to Residues in Both Extracellular Loops and Transmembrane DomainsJillian G. Baker, Stephen J. Hill, Richard G. W. Proudman|Molecular Pharmacology|2014Cited by 25
The affinity and selectivity of α‐adrenoceptor antagonists, antidepressants and antipsychotics for the human α2A, α2B, and α2C‐adrenoceptors and comparison with human α1 and β‐adrenoceptorsRichard G. W. Proudman, Jillian G. Baker, Juliana Akinaga|Pharmacology Research & Perspectives|2022Cited by 23